Business, Health

Maricann Group Receives Encapsulated Cannabis Oil License From Health Canada

A canadian subsidiary, the Maricann Group, will begin production of encapsulated cannabis oil, following receipt of its production license from Health Canada on November 17, 2017.

Maricann expects patients to be able to order oil capsules starting in the first quarter of 2018, but also subject to Health Canada’s issuance of the required license to sell.

What Is Encapsulated Cannabis Oil?

Maricann Capsules are a critical innovation in medicinal cannabis therapy as they deliver medicine in a dosage form widely utilized in the pharmaceutical industry, provide precise dosing in each capsule, enhance patient compliance and will be formulated to support therapeutic efficacy.

All natural cannabis extract will be delivered in a vegan capsule format, initially in four products: 15mg and 25mg cannabidiol (CBD) capsules and 5mg and 10mg THC capsules, allowing physicians and patients to more easily control dosing and choose the cannabinoid therapy they prefer.


When Does Production Begin?

Maricann will being their production of its exclusive and patented VesiSorb technology in capsule format. VesiSorb is approved in the delivery of other lipophilic (fat-soluble pharmaceutical and nutraceutical formulations) drugs by Health Canada, the US Food and Drug Administration and European Medicines Agency.

Application of VesiSorb is not limited to capsules, but spans entire product categories of ingestibles, including capsules, edibles and functional beverages.

“Physicians and patients understand metered dose capsules, they’re a part of daily life. Vaporizing and smoking aren’t something people new to cannabis are familiar or comfortable with, so we believe that providing them with a treatment option in a delivery format they understand is compelling,” said Ben Ward, CEO of Maricann.

Everyone Wins

“Medicinal cannabinoids have anecdotally demonstrated therapeutic benefit for a wide range of symptoms; however, cannabinoids are nearly insoluble in water. Their poor solubility and low dissolution rate in the aqueous gastrointestinal fluids and significant first-pass liver metabolism result in low and unpredictable oral cannabinoid bio-availability. Consequentially, cannabinoids will require high doses to reach therapeutic plasma concentrations, especially when ingested. At Maricann, we are focused on formulations that actually potentiate the components of the cannabis plant.”

Maricann offers true differentiation with our full acquisition of the global rights for Vesisorb technology for phytocannabinoids.

Facebook Comments